ArticleFrontiers in pharmacology2025
Integrated proteomics analysis and network pharmacology to elucidate the mechanism of Zhilong Huoxue Tongyu Capsule alleviate hypertensive retinopathy in Ang II infusion mice model.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zhilong Huoxue Tongyu Capsule (ZLHXTY) has been used in clinical treatment of vascular diseases caused by hypertension over 20 years. However, the specific mechanisms by ZLHXTY alleviate hypertensive retinopathy (HR) needs to be further explored. Materials and methods: HR mouse model was established by infusing Ang II via subcutaneously implanted osmotic mini-pumps, followed by oral administration of ZLHXTY (0.35, 0.7, 1.4 g/kg/day) 28 days for treatment. To assess the impacts of ZLHXTY on retinal neurodegeneration and vascular injury, multiple experiments such as OCTA, ERG and HE staining were performed. Subsequently, network pharmacological and 4D-label-free proteomics to clarify the potential targets and mechanisms of ZLHXTY alleviated HR. Finally, Western blot, ELISA, IF, and other techniques were utilized to detect the expression of proteins related to inflammation, oxidative stress, and NLRP3 inflammasome activation. Results: ZLHXTY significantly alleviated retinal dysfunction, increased retinal blood flow, and mitigated pathological changes such as retinal tissues edema in HR mice. Network pharmacology indicated that ZLHXTY might exert anti-inflammatory and anti-oxidative stress effects through targets such as TNF and NF-κB. Proteomic analysis showed that the differential proteins between the ZL group and the Ang II group were mainly enriched in the immune-inflammatory response, and the main mechanism of which might be related to the assembly of NLRP3 inflammasome. Subsequent Conclusion: Our results suggest that ZLHXTY by regulating the NLRP3/Caspase-1/GSDMD axis, inhibiting pyroptosis, thereby relieving retinal dysfunction and vascular injury in HR mice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.